CFPS expansion Creative Biogene’s launch of cell-free protein synthesis kits signals a growing portfolio beyond traditional cell-based platforms. This creates cross-sell opportunities to researchers seeking rapid protein production without cell culture, aligning with both early discovery and screening workflows.

Gene delivery breadth With ongoing offerings in recombinant adenoviruses, AAV, and lentiviruses for gene delivery and knockdown, there is potential to upsell integrated solutions for gene therapy research programs, including associated services like vector development, purification, and quality control.

CRISPR & PEM-Seq Recent launches in single cell CRISPR library screening and PEM-Seq support position Creative Biogene as a partner for CRISPR-Cas9 platform optimization. Sales opportunities exist in upgrading customers to advanced genomic screening services and validation pipelines.

GMP capabilities The introduction of GMP lentivirus production service highlights compliance and scalable manufacturing. This could open doors to collaborations with biotech startups and academic labs transitioning to clinical or translational studies requiring GMP-grade vectors.

Global service dark As a global provider serving biotechnology and pharma clients, Creative Biogene can leverage offshore and on-demand outsourcing trends. Propose bundled outsourcing packages combining vector production, CFPS kits, and CRISPR services to expand account value with existing clients and win multi-project deals.